Infection profile of immune-modulatory drugs used in autoimmune diseases: analysis of summary of product characteristic data
Objective Serious infection remains a concern when prescribing immune-modulatory drugs for immune-mediated inflammatory diseases. The ‘summary of product characteristics’ (SmPCs) provide information on adverse events for example, infections, from clinical trials and postmarketing pharmacovigilance.T...
Main Authors: | Catherine Smith, Andrew Cope, Elena Nikiphorou, Mrinalini Dey, James Galloway, Kimme L Hyrich, Katie Bechman, Sizheng Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-11-01
|
Series: | RMD Open |
Online Access: | https://rmdopen.bmj.com/content/8/2/e002621.full |
Similar Items
-
Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases
by: George E Fragoulis, et al.
Published: (2022-11-01) -
Beverages in Rheumatoid Arthritis: What to Prefer or to Avoid
by: Mrinalini Dey, et al.
Published: (2020-10-01) -
Fatigue in Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Comparison of Mechanisms, Measures and Management
by: Mrinalini Dey, et al.
Published: (2021-08-01) -
Understanding the psychosocial determinants of effective disease management in rheumatoid arthritis to prevent persistently active disease: a qualitative study
by: Heidi Lempp, et al.
Published: (2024-04-01) -
Tumor Activated Cell Penetrating Peptides to Selectively Deliver Immune Modulatory Drugs
by: Dina V. Hingorani, et al.
Published: (2021-03-01)